▪ Process Optimization: Streamlined project workflow and enabled more cross-functional teamwork and effective communication, which contributed to breakthrough progress to develop first-in-class medicine in pain market, projected to be $52B in 2022.▪ Innovative Solution: Developed and implemented novel evaluation model for clinical study risk assessment that ensured controlled quality analysis, helping Vertex enhance the success for drug discovery and conserve upfront investment.▪ Cross-Functional Project Management: Led the formulation group in cross-functional pre-clinical drug discovery project team; delivered 5 new drugs into clinical study, broadening company’s pipeline and driving strong momentum of innovation.

▪ Market & Company Analysis: Led the market analysis of a specialized product and a detailed analysis of target company Vornia and identified high growth potential through acquisition and leveraging IP advantage.▪ M&A Integration: Completed acquisition of chemical company Vornia with an aim to enter new market of sterilized injectable formulation, valued at over $700M in 2019; the growth of the new product remained strong even during the Covid pandemic.▪ Client Engagement: Work directly with clients to resolve clients’ (pharmaceuticals) service problems related to product application and regulatory affairs, sustaining exceptional customer satisfaction, which led to repeat sales and further collaboration with Ashland.

▪ Growth Strategy: Assembled comprehensive patent research and determined strategy to mitigate potential risk during Ashland’s acquisition of Vornia, ultimately helping company to expand product pipeline and enter new market.▪ Product Development: Initiated novel application platform for new product and contributed in a cross-functional team to develop product marketing plan and expand portfolio, presenting final recommendations to key stakeholders.